Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder

Journal of Mental Health Policy and Economics

Volumn 13, Issue 1, 2010, Pages

  Snedecor, Sonya J ^a   Botteman, Marc F ^a   Schaefer, Kendyl ^b   Sarocco, Phillip ^b   Barry, Nadine ^b   Pickard, A Simon ^c  

^a PHARMERIT INTERNATIONAL   (United States)

^b SUNOVION PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESZOPICLONE; FLUOXETINE; PLACEBO;

ABSENTEEISM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG WITHDRAWAL; ECONOMIC ASPECT; EMPLOYMENT STATUS; EVENING DOSAGE; HAMILTON SCALE; HEALTH CARE COST; HUMAN; INSOMNIA; JOB PERFORMANCE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; PRODUCTIVITY; PSYCHOPHARMACOTHERAPY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 12; STRUCTURED QUESTIONNAIRE;

ABSENTEEISM; ALGORITHMS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; AZABICYCLO COMPOUNDS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG COSTS; FLUOXETINE; HUMANS; HYPNOTICS AND SEDATIVES; PERSONALITY INVENTORY; PIPERAZINES; PSYCHOMETRICS; QUALITY-ADJUSTED LIFE YEARS;

EID: 77952800241     PISSN: 10914358     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Thase, ME. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry 1999; 60 (Suppl 17): 28-31.
2. Brunello N, Armitage R, Feinberg I, Holsboer-Trachsler E, Leger D, Linkowski P, Mendelson WB, Racagni G, Saletu B, Sharpley AL, Turek F, VanCauter E, Mendlewicz J. Depression and sleep disorders: clinical relevance, economic burden and pharmacological treatment. Neuropsychobiology 2000; 242: 107-119.
3. Katz DA, McHorney CA. The relationship between insomnia and health-related quality of life in patients with chronic illness. J Fam Pract 2002; 51: 229-235.
4. Kuppermann M, Lubeck DP, Mazonson PD, Patrick DL, Stewart AL, Buesching DP, Fifer SK. Sleep problems and their correlates in a working population. J Gen Intern Med 1995; 10: 25-32.
5. Saarijarvi S, Salminen JK, Toikka T, Raitasalo R. Health-related quality of life among patients with major depression. Nord J Psychiatry 2002; 56: 261-264.
6. Simon GE, Revicki D, Heiligenstein J, Grothaus L, VonKorff M, Katon WJ, Hylan TR,. Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry 2000; 22: 153-162.
7. Thase ME. The clinical, psychosocial, and pharmacoeconomic ramifications of remission. Am J Manag Care 2001; 7: S377-S385.
8. Martin SA, Aikens JE, Chervin RD. Toward cost-effectiveness analysis in the diagnosis and treatment of insomnia Sleep Med Rev 2004; 8: 63-72.
9. Fava M. Daytime sleepiness and insomnia as correlates of depression. J Clin Psychiatry 2004; 65 Suppl 16: 27-32.
10. Asnis GM, Chakraburtty A, DuBoff EA, Krystal A, Londborg PD, Rosenberg R, Roth-Schechter B, Scharf MB, Walsh J.K. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry 1999; 60: 668-676.
11. Cohn JB. Triazolam treatment of insomnia in depressed patients taking tricyclics. J Clin Psychiatry 1983; 44: 401-406.
12. Nolen WA, Haffmans PM, Bouvy PF, Duivenvoorden HJ. Hypnotics as concurrent medication in depression. A placebo-controlled, double-blind comparison of flunitrazepam and lormetazepam in patients with major depression, treated with a (tri)cyclic antidepressant. J Affect Disord 1993; 28: 179-188.
13. Fava M, McCall WV, Krystal A, Wessel T, Rubens R, Caron J, Amato D, Roth T. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 2006; 59: 1052-1060.
14. Botteman MF, Ozminkowski RJ, Wang S, Pashos CL, Schaefer K, Foley DJ. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model. CNS Drugs 2007; 21: 319-334.
15. Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med 2001; 2: 297-307.
16. Ware JE. SF-36 Health Survey: Manual and Interpretation Guide Quality Metric Inc,. 2003.
17. Lerner D, Amick BC, III, Rogers WH, Malspeis S, Bungay K, Cynn D. The Work Limitations Questionnaire. Med Care 2001; 39: 72-85.
18. Simon GE, Chisholm D, Treglia M, Bushneil D. Course of depression, health services costs, and work productivity in an international primary care study. Gen Hosp Psychiatry 2002; 24: 328-335.
19. NICE. Guide to the methods of technology appraisal. London: National Institute for Health and Clinical Excellence; June 2008. http://www.nice.org.uk/ media/B52/A7/ TAMethodsGuideUpdatedJune2008.pdf. Accessed November 5, 2009.
20. Lave JR, Frank RG, Schulberg HC, Kamlet MS. Cost-effectiveness of treatments for major depression in primary care practice. Arch Gen Psychiatry 1998; 55: 645-651.
21. Pyne JM, Tripathi S, Williams DK, Fortney J. Depression-free day to utility-weighted score: is it valid? Med Care 2007; 45: 357-362.
22. Franks P, Lubetkin EI, Gold MR, Tancredi DJ, Jia H. Mapping the SF-12 to the EuroQol EQ-5D Index in a national US sample. Med Decis Making 2004; 24: 247-254.
23. Gray AM, Rivero-Arias O, Clarke PM. Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Med Decis Making 2006; 26: 18-29.
24. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002; 21: 271-292.
25. Simon GE, Khandker RK, Ichikawa L, Operskalski BH. Recovery from depression predicts lower health services costs. J Clin Psychiatry 2006; 67: 1226-1231.
26. Bureau of Labor Statistics. EMPLOYER COSTS FOR EMPLOYEE COMPENSATION-SEPTEMBER 2007, Table. 1 - Employer costs per hour worked for employee compensation and costs as a percent of total compensation: Civilian workers, by major occupational and industry group, September 2007. US Department of Labor [2007; Available at: http://www.bls.gov/news.release/pdf/ecec.pdf. Accessed Mar 3, 2008.
27. Bureau of Labor Statistics. THE EMPLOYMENT SITUATION: DECEMBER 2007. Table A. Major indicators of labor market activity, seasonally adjusted. Total private hours of work. US Department of Labor [2007; Available at: http://www.bls.gov/news.release/archives/empsit-01042008.pdf. Accessed Mar 3, 2008
28. Red Book: Pharmacy's Fundamental Reference. Oxford: Blackwell, 2007.
29. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7: 518-528.
30. Grant Thornton LLP. Cost of Dispensing Study: An Independent Comparative Analysis of US Prescription Dispensing Costs. 2007.
31. Krystal A, Fava M, Rubens R, Wessel T, Caron J, Wilson P, Roth T, McCall WV. Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. J Clin Sleep Med 2007; 3: 48-55.
32. Nierenberg AA, Keefe BR, Leslie VC, Alpert JE, Pava JA, Worthington JJ, III, Rosenbaum JF, Fava M. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 1999; 60: 221-225.
33. Appleby J, Devlin N, Parkin D. NICE'S cost-effectiveness threshold. Brit Med J 2007; 335: 358-359.
34. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20: 332-342.
35. McCall WV. A psychiatric perspective on insomnia. J Clin Psychiatry 2001; 62 (Suppl 10): 27-32.
36. Reynolds CF, III, Frank E, Houck PR, Mazumdar S, Dew MA, Cornes C, Buysse DJ, Begley A, Kupfer DJ. Which elderly patients with remitted depression remain well with continued interpersonal psychotherapy after discontinuation of antidepressant medication? Am J Psychiatry 1997; 154: 958-962.
37. Walsh JK, Krystal AD, Amato DA, Rubens R, Caron J, Wessel TC, Schaefer K, Roach J, Wallenstein G, Roth T. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007; 30: 959-968.
38. Donald SC, Unutzer J, Schoenbaum M, Duan N, Lenert LA, Sturm R, Wells KB. Can utility-weighted health-related quality-of-life estimates capture health effects of quality improvement for depression? Med Care 2001; 39: 1246-1259.
39. Brazier J, Dixon S. The use of condition specific outcome measures in economic appraisal. Health Econ 1995; 4: 255-264.